Psychiatric Quarterly

, Volume 62, Issue 4, pp 299–309 | Cite as

Neuroleptic malignant syndrome: A complication of neuroleptics and cocaine abuse

  • MaCaulay J. Akpaffiong
  • Pedro Ruiz
Articles

Abstract

One hundred and sixty psychiatric patients on Neuroleptics, with and without a history of substance abuse were daily monitored in order to establish the incidence of neuroleptic malignant syndrome in these two groups. Four (5.1%) of the cocaine abusers and none of the non-cocaine abusers developed neuroleptic malignant syndrome when treated with neuroleptics. Thus we argue that psychiatric patients with a history of cocaine abuse may be more at risk of developing neuroleptic malignant syndrome when treated with neuroleptics, possibly associated with the blockade of dopamine (D2-receptors) by neuroleptics and the activation of dopamine/5-HT receptors by cocaine-induced dopamine.

Keywords

Public Health Dopamine Cocaine Substance Abuse Psychiatric Patient 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shalev A, Munitz H: The Neuroleptic malignant syndrome: Agent and host interaction. Acta Psychiatrica Scandinavica; 73: 37–347, 1986.Google Scholar
  2. 2.
    Guze BH, Baxter, LR: Current concepts neuroleptic malignant syndrome. New England Journal of Medicine 313: 163–166. 1985.Google Scholar
  3. 3.
    Kurlan R, Hamil R, Shoulson I: Neuroleptic malignant syndrome. Clinical neuropharmacology, 7: 109–120, 1984.Google Scholar
  4. 4.
    Caroff SN: Neuroleptic malignant syndrome. Journal of Clinical Psychiatry 41: 79–83, 1980.Google Scholar
  5. 5.
    Addonizio A, Susman VL, Roth SD: Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. American Journal of Psychiatry 143: 1587–1590, 1986.Google Scholar
  6. 6.
    Keck PE, Pope HG, McElroy SL: Frequency and presentation of neuroleptic malignant syndrome: A prospective study. American Journal of Psychiatry 144: 1344–1346, 1987.Google Scholar
  7. 7.
    Kosten TR, Kleber HD: Rapid death during Cocaine abuse: A variant of the neuroleptic malignant syndrome? American Journal of Drug Alcohol Abuse 14(3): 335–346, 1988.Google Scholar
  8. 8.
    Levinson DF, Simpson GM: Neuroleptic-induced extrapyramidal symptoms with fever. Archives of General Psychiatry 43: 839–848, 1986.Google Scholar
  9. 9.
    Yamawaki S, Lai H, Horita A: Dopaminergic and serotonergic mechanisms of thermoregulation: Mediation of thermal effects of apomorphine and dopamine. Journal of Pharmacology and Experimental Therapeutics 227: 383–388, 1983.Google Scholar
  10. 10.
    McLellan TA, Woody SE, O'Brien CP: Development of Psychiatric Illness in Drug Abusers. New England Journal Medicine 301: 1310–1314, 1979.Google Scholar
  11. 11.
    Cleghorn JM, Kaplan RD, Szechtman B: Substance abuse and schizophrenia: Effect on symptoms but not on neurocognitive function. Journal of Clinical Psychiatry 52: 26–30, 1991.Google Scholar
  12. 12.
    Pope HG, Keck PE, McElroy SL: Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry, 143: 1227–1233, 1986.Google Scholar
  13. 13.
    Lew TY, Tollefson G: Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biological Psychiatry 18: 1441–1446, 1983.Google Scholar
  14. 14.
    Itoh H, Ohtsuka N, Ogitak K, Yagi G, Miura S and Koga Y: Malignant neuroleptic syndrome—Its present status in Japan and clinical problems. Folia Psychiatry et Neurologic Japanica 31: 559–576, 1977.Google Scholar
  15. 15.
    Grunhaus L, Sancovici S, Rimon R: Neuroleptic malignant syndrome due to depot fluphenazine. Journal of Clinical Psychiatry 40: 99–100, 1979.Google Scholar
  16. 16.
    Henderson VW, Wooten GF: Neuroleptic malignant syndrome: A pathogenetic role for dopamine receptor blockade? Neurology (Ng) 31: 132–137, 1981.Google Scholar
  17. 17.
    Weinberg S, Twersky RS: Neuroleptic malignant syndrome. Anesthesia Analgesia 62: 848–850, 1983.Google Scholar
  18. 18.
    Lin MT: Effects of dopaminergic antagonist and agonist on thermoregulation in rabbits. Journal of Physiology 293: 217–228, 1979.Google Scholar
  19. 19.
    Burke R, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH: Neuroleptic malignant syndrome caused by dopamine depleting agents in a patient with Huntington's disease. Neurology 31: 1022–1026, 1981.Google Scholar
  20. 20.
    Friedhoff AJ, Alpert M: Receptor sensitivity modification as a potential treatment. In: Lipton MA, Dimuscio A, Killam KF, eds, Psychopharmacology: A generation of Progress, New York, New York: Raven Press 797–801, 1978.Google Scholar
  21. 21.
    Taylor D, Ho BT: Neurochemical effects of cocaine following acute and repeated injection. Journal of Neuroscience Research 3: 95–101, 1977.Google Scholar
  22. 22.
    Memo M, Pradham S, Hanbauer I: Cocaine induced supersensitivity of striatal dopamine receptors: Role of endogenous calmodulin. Neuropharmacology 20: 1145–1150, 1981.Google Scholar
  23. 23.
    Post RM, Frontier in Affective Disorder Research: New pharmacological agents and new methodologies. In: Lipton MA, DiMascio A, Killam KF, (eds). Psychopharmacology: A Generation of Progress. New York, Raven Press 1323–1335, 1978.Google Scholar
  24. 24.
    Memon W, Vivonia CA: Modification of apomorphine hypothermia by drugs affecting brain 5 hydroxytryptamine function. European Journal of Pharmacology 76: 223–227, 1981.Google Scholar
  25. 25.
    Van Rossum: The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H, Cole JO, Deniker P, Hippius H, Bradley PB, (eds). Proceedings of the 5th collequim international neuropsychopharmacologicum. Excerpta medica foundation, Amsterdam 321–329, 1967.Google Scholar

Copyright information

© Human Sciences Press, Inc. 1991

Authors and Affiliations

  • MaCaulay J. Akpaffiong
  • Pedro Ruiz
    • 1
  1. 1.Dept. of PsychiatryBaylor College of MedicineHouston

Personalised recommendations